Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2024-02-23 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司监事会关于公司调整2023年度向特定对象发行A股股票相关事项的书面审核意见
Capital/Financing Update Classification · 95% confidence The document is a written supervisory board opinion regarding the company's adjustment of a specific issuance of A shares in 2023. It references legal compliance and approval of extending the validity period of a shareholder meeting resolution related to the issuance. The content focuses on the supervisory board's review and approval of capital issuance matters, specifically a targeted share issuance. The document length is short (906 characters) and it is not a full financial report but an official opinion on a capital issuance matter. This fits best under Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes.
2024-02-23 Chinese
金陵药业股份有限公司第九届监事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jinling Pharmaceutical Co., Ltd. regarding the extension and adjustment of the validity period for a specific issuance of A shares in 2023. It includes details about the meeting, voting results, and references to related audit opinions. The content focuses on board/committee decisions and approvals rather than financial results or reports. It is not an annual or interim report, earnings release, or audit report. It is also not a proxy solicitation or voting result announcement. The document is a formal announcement of board-level decisions, fitting the category of Board/Management Information (MANG). The document length is short and contains no financial statements or detailed financial data, confirming it is a management/board announcement rather than a report.
2024-02-23 Chinese
金陵药业股份有限公司2024年第二次独立董事专门会议的审查意见
Board/Management Information Classification · 95% confidence The document is titled as the "2024 Second Independent Directors Special Meeting Review Opinions" of Jinling Pharmaceutical Co., Ltd. It references specific legal regulations and discusses opinions on proposals related to extending the validity period of a shareholder meeting resolution and authorizing the board to handle matters related to a specific stock issuance. The document is a formal opinion from independent directors on corporate governance matters, specifically related to board and shareholder meeting decisions. It does not contain financial statements, earnings data, or audit information. It is not a report or announcement of voting results but rather a management/board-related opinion document. Therefore, the best fitting category is Board/Management Information (MANG). The document length is short and focused on board-level decisions and opinions, consistent with MANG filings.
2024-02-23 Chinese
金陵药业股份有限公司关于召开2024年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2024 second extraordinary general meeting of shareholders for Jinling Pharmaceutical Co., Ltd. It includes details about the meeting date, voting procedures, proposals to be discussed, and instructions for shareholders to register and vote. There are no financial statements or financial performance data presented. The document is primarily an announcement informing shareholders about the meeting and how to participate, rather than the report or results of the meeting itself. The document length is under 5,000 characters, consistent with a notice rather than a full report. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2024-02-23 Chinese
金陵药业股份有限公司第九届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the ninth meeting of the ninth board of directors of Jinling Pharmaceutical Co., Ltd. It details the meeting date, voting results, and specific agenda items related to extending the validity period of a shareholder resolution on a specific A-share issuance and authorizations related to that issuance. It also references upcoming shareholder meetings and related announcements published elsewhere. The document does not contain financial statements or detailed financial data but is a formal disclosure of board decisions and meeting outcomes. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document length is short (1689 characters), and it is not a report publication announcement or regulatory filing. Therefore, the best classification is MANG with high confidence.
2024-02-23 Chinese
江苏泰和律师事务所关于金陵药业股份有限公司2024年第一次临时股东大会的法律意见书
Regulatory Filings
2024-01-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.